摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Tetrahydrodicyclopentadienylamin | 94647-14-0

中文名称
——
中文别名
——
英文名称
Tetrahydrodicyclopentadienylamin
英文别名
Dicyclopent-2-en-yl-amin;N-cyclopent-2-en-1-ylcyclopent-2-en-1-amine
Tetrahydrodicyclopentadienylamin化学式
CAS
94647-14-0
化学式
C10H15N
mdl
MFCD19219800
分子量
149.236
InChiKey
XPSPYXYYVDZRET-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    1

文献信息

  • NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE
    申请人:Okano Akihiro
    公开号:US20120157459A1
    公开(公告)日:2012-06-21
    [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, —NR 7 —; and R 1 to R 7 are specific groups), a salt of the compound, or a solvate of the salt or the compound.
    提供一个以新型化合物作为活性成分的GPR40激活剂,该化合物具有GPR40激动剂作用,该化合物的盐,该盐或化合物的溶剂合物,或者类似物,尤其是胰岛素分泌促进剂以及对糖尿病、肥胖症或其他疾病的预防及/或治疗剂。[解决该问题的方法] 公式(I)的化合物:(其中n为0至2;p为0至4;j为0至3;k为0至2;环A是一个芳基团,可选择性被L取代或是一个杂环团,可选择性被L取代;环B是一个苯环、一个吡啶环或一个嘧啶环;X是O,S,—NR7—;R1至R7是特定基团),该化合物的盐,或该盐或化合物的溶剂合物。
  • CYCLIC AMIDE DERIVATIVE
    申请人:Okano Akihiro
    公开号:US20130203739A1
    公开(公告)日:2013-08-08
    [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (1): (where n is 0 to 2; p is 0 to 4; h is 0 to 3; j is 0 to 3; k is 0 to 2; a ring B is an aryl group or a heteroaryl group; X is O, S, or —NR 7 —; J 1 is —CR 11a R 11b — or —NR 11c —; J 2 is —CR 12a R 12b — or —NR 12c —; and R 1 to R 12c are specific groups), a salt of the compound, or a solvate of the salt or the compound.
    为提供一种具有GPR40激活剂作用的新化合物、该化合物的盐、盐或化合物的溶剂合物,尤其是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药剂,解决问题的方法是使用Formula (1)的化合物:(其中n为0至2;p为0至4;h为0至3;j为0至3;k为0至2;环B为芳香族或杂环芳基;X为O、S或-NR7-;J1为-CR11aR11b-或-NR11c-;J2为-CR12aR12b-或-NR12c-;R1到R12为特定基团),该化合物的盐,或盐或化合物的溶剂合物。
  • NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE
    申请人:OHKOUCHI Munetaka
    公开号:US20120277150A1
    公开(公告)日:2012-11-01
    [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is 0 or —NR 7 —; and R 1 to R 7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.
    提供一种包含GPR40激活剂的药剂,其活性成分为具有GPR40激动剂作用的新化合物、该化合物的盐、该化合物或盐的溶剂化合物等,特别是胰岛素促分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药物。解决问题的方法是使用式(I)的化合物:(其中p为0至4;j为0至2;k为0至1;环A为芳基、杂环基、环烷基、环烯基、螺环基;环B为芳基、杂芳基;X为0或-NR7-;R1至R7和L为特定基团),该化合物的盐或该化合物或盐的溶剂化合物。
  • NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES
    申请人:MOCHIDA PHARMACEUTICAL CO., LTD.
    公开号:US20130210721A1
    公开(公告)日:2013-08-15
    [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is O or —NR 7 —; and R 1 to R 7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.
    [目的] 提供一种GPR40激活剂,其中包含一种具有GPR40激动剂作用的新化合物作为活性成分,该化合物的盐、化合物或盐的溶剂合物等,特别是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖症或其他疾病的药物。 [解决问题的方法] 公式(I)的化合物: 其中p为0至4;j为0至2;k为0至1;环A为芳基、杂环基、环烷基、环烯基、螺环基;环B为芳基、杂芳基;X为O或-NR7-;R1至R7和L为特定的基团,该化合物的盐或化合物或盐的溶剂合物。
  • ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, MODULE AND COMPOUND
    申请人:DAIKIN INDUSTRIES, LTD.
    公开号:EP3761435A1
    公开(公告)日:2021-01-06
    The disclosure provides an electrolyte solution that gives an electrochemical device having low resistance. The electrolyte solution contains a compound represented by the following formula (1). In the formula, R101 and R102 are each individually a substituent such as a C1-C7 alkyl group, the substituent optionally contains at least one divalent to hexavalent hetero atom in a structure or optionally has a structure obtained by replacing at least one hydrogen atom by a fluorine atom or a C0-C7 functional group, and at least one selected from the group consisting of R101 and R102, when both being an alkyl group, contains at least one divalent to hexavalent hetero atom in the structure or has a structure obtained by replacing at least one hydrogen atom by a fluorine atom or a C0-C7 functional group.
    本公开提供了一种电解质溶液,它能使电化学装置具有低电阻。该电解质溶液含有下式(1)所代表的化合物。式中,R101 和 R102 分别是取代基,如 C1-C7 烷基,取代基在结构中任选含有至少一个二价至六价杂原子,或任选具有通过用原子或 C0-C7 官能团取代至少一个氢原子而得到的结构、且至少有一个选自 R101 和 R102(当两者均为烷基时)组成的组,在结构上含有至少一个二价至六价杂原子,或具有通过用原子或 C0-C7 官能团取代至少一个氢原子而获得的结构。
查看更多